Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Pancreatic Neoplasms 2Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Neoplasms by Histologic Type 1Multiple Myeloma 1Lung Neoplasms 1Head and Neck Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Melphalan 16Dexamethasone 15Bortezomib 11Peripheral Blood Stem Cell Transplantation 9Lenalidomide 9fludarabine phosphate 8Calcium Dobesilate 7pomalidomide 5fludarabine 5Busulfan 5carfilzomib 4Radiotherapy 4Prednisone 4Cyclophosphamide 4liposomal doxorubicin 3daratumumab 3Tacrolimus 3Mycophenolic Acid 3Methotrexate 3Filgrastim 3Cyclosporine 3Arsenic Trioxide 3Alemtuzumab 3samarium Sm-153 lexidronam 2holmium-1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetrakis(methylenephosphonic acid) 2Whole-Body Irradiation 2Surveys and Questionnaires 2Pneumococcal Vaccines 2Granulocyte Colony-Stimulating Factor 2Bendamustine Hydrochloride 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Neoplasms, Plasma Cell × siltuximab × Clear all
NCT01531998 2015-06-19

Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM)

M.D. Anderson Cancer Center

Phase 1/2 Completed
14 enrolled 6 charts
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡